Novavax (NVAX): Exploring Valuation After Prolonged Share Price Weakness

Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...

Former FDA commissioners raise alarm over new vaccine policy

The US Food and Drug Administration’s new vaccine approval philosophy upends established regulatory practices and could put the health and safety of Americans at risk, according to an article written ...
The Business Journals

Novavax shareholder Shah Capital urges vaccine maker to explore sale amid market struggles

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...